We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
Cap. Flow
+$66M
Cap. Flow %
1.4%
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$135M
2
AZN icon
AstraZeneca
AZN
+$85.6M
3
BAX icon
Baxter International
BAX
+$72.7M
4
AVTR icon
Avantor
AVTR
+$60.9M
5
UNH icon
UnitedHealth
UNH
+$55.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$126M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$92.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
4
EXAS
Exact Sciences
EXAS
+$35.2M
5
CMPS
Compass Pathways
CMPS
+$34.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.5%
3 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$37.2B
$62.7M 1.33%
370,000
-57,000
-13% -$10.6M
UNH icon
27
UnitedHealth
UNH
$379B
$61.8M 1.31%
+123,100
New +$55.7M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$122B
$61.5M 1.3%
280,000
-646,400
-70% -$126M
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.54B
$60.4M 1.28%
2,553,000
+116,000
+5% +$2.69M
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.65B
$58.9M 1.25%
700,000
+245,000
+54% +$19.9M
ARWR icon
31
Arrowhead Research
ARWR
$12B
$58M 1.23%
875,000
+201,300
+30% +$13.8M
STVN icon
32
Stevanato
STVN
$5.41B
$57.1M 1.21%
2,541,893
– –
GRTS
33
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$56.2M 1.19%
4,370,000
-87,831
-2% -$973K
KZR
34
DELISTED
Kezar Life Sciences
KZR
$54M 1.14%
322,820
+296,820
+1,142% +$33.5M
ACET icon
35
Adicet Bio
ACET
$75.3M
$53.1M 1.13%
189,625
+38,400
+25% +$6.59M
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$43.1M 0.92%
1,815,000
+170,000
+10% +$4.06M
KYMR icon
37
Kymera Therapeutics
KYMR
$9.05B
$42.5M 0.9%
670,000
+155,500
+30% +$9.06M
IMCR icon
38
Immunocore
IMCR
$1.72B
$42.1M 0.89%
1,230,000
+134,400
+12% +$4.87M
CRBU icon
39
Caribou Biosciences
CRBU
$158M
$40.4M 0.86%
2,674,067
+200,000
+8% +$3.89M
INSM icon
40
Insmed
INSM
$22.7B
$39.5M 0.84%
1,450,000
+158,000
+12% +$4.52M
OCDX
41
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$38.3M 0.81%
1,790,000
-608,000
-25% -$12M
PHAT icon
42
Phathom Pharmaceuticals
PHAT
$953M
$37.3M 0.79%
+1,896,000
New +$44.6M
EPIX
43
DELISTED
ESSA Pharma
EPIX
$34.9M 0.74%
2,460,000
+10,000
+0.4% +$111K
AMN icon
44
AMN Healthcare
AMN
$1.3B
$34.3M 0.73%
+280,100
New +$31.1M
LEGN icon
45
Legend Biotech
LEGN
$3.73B
$33.2M 0.7%
711,900
-182,100
-20% -$9.24M
ATEC icon
46
Alphatec Holdings
ATEC
$1.33B
$31.7M 0.67%
2,773,000
-13,000
-0.5% -$153K
BLU
47
DELISTED
BELLUS Health Inc.
BLU
$30.4M 0.64%
3,775,000
-1,167,000
-24% -$7.74M
VIR icon
48
Vir Biotechnology
VIR
$1.48B
$29.3M 0.62%
700,000
+185,000
+36% +$7.25M
AXSM icon
49
Axsome Therapeutics
AXSM
$12.3B
$29.3M 0.62%
+775,000
New +$28.5M
SPNE
50
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$27.4M 0.58%
2,010,000
+67,000
+3% +$962K
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2021 Portfolio in Review

As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management's Q4 2021 filing shows 15 new, 43 increased, 17 reduced and 23 closed positions. Its largest new stake was Elevance Health: 321,000 shares worth $149M. The largest sale was Vertex Pharmaceuticals, an estimated $126M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

  • Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
  • Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
  • Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
  • Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
  • Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.

Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.